Gynecological Cancer
- Corpus Uteri, OvaryA Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)Principal Investigator: Alessandro Santin
- Corpus UteriA Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial CancerPrincipal Investigator: Gloria Huang
- Liver, Lung, Melanoma, skin, Other Female GenitalPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial CarcinomaPrincipal Investigator: Mario Sznol
- Corpus UteriA Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial CancerPrincipal Investigator: Alessandro Santin
- Other Female Genital, OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumPrincipal Investigator: Gary Altwerger